▶ 調査レポート

乳がんPARP阻害剤の世界市場予測 2024年：企業別、地域別、種類・用途別（～2024）
• 英文タイトル：Global PARP Inhibitors for Breast Cancer Market 2019 by Company, Regions, Type and Application, Forecast to 2024

GlobalInfoResearchが調査・発行した産業分析レポートです。乳がんPARP阻害剤の世界市場予測 2024年：企業別、地域別、種類・用途別（～2024） / Global PARP Inhibitors for Breast Cancer Market 2019 by Company, Regions, Type and Application, Forecast to 2024 / B-GIR08C4300資料のイメージです。• レポートコード：B-GIR08C4300
• 出版社/出版日：GlobalInfoResearch / 2019年8月
※2024年版があります。お問い合わせください。
• レポート形態：英文、PDF、104ページ
• 納品方法：Eメール
• 産業分類：Pharma & Healthcare
• 販売価格（消費税別）
  Single User￥522,000 (USD3,480)▷ お問い合わせ
  Corporate User￥1,044,000 (USD6,960)▷ お問い合わせ
• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
本調査レポートは、乳がんPARP阻害剤の世界市場について調べ、まとめました。種類別セグメントは、オラパリブ、タラゾパリブ等、用途別セグメントは、携帯電話アクセサリー店、3C小売店、個人等に区分しました。乳がんPARP阻害剤の世界市場概観、企業動向、企業別乳がんPARP阻害剤シェア、市場規模推移、市場規模予測（2019年-2024年）、主要地域分析（北米、ヨーロッパ、アジア等）、主要国分析（日本、中国、アメリカ等）データなどの情報が含まれています。
・乳がんPARP阻害剤の市場概観
・乳がんPARP阻害剤の企業概要（事業概要、製品種類、販売量、価格、売上、市場シェア等）
・乳がんPARP阻害剤の企業別販売動向、市場シェア、市場集中度、競争動向
・乳がんPARP阻害剤の世界市場規模
・乳がんPARP阻害剤の北米市場分析（アメリカ、カナダ、メキシコ等）
・乳がんPARP阻害剤のアメリカ市場規模推移
・乳がんPARP阻害剤のカナダ市場規模推移
・乳がんPARP阻害剤のメキシコ市場規模推移
・乳がんPARP阻害剤のヨーロッパ市場分析（ドイツ、イギリス、ロシア、フランス、イタリア等）
・乳がんPARP阻害剤のドイツ市場規模推移
・乳がんPARP阻害剤のイギリス市場規模推移
・乳がんPARP阻害剤のロシア市場規模推移
・乳がんPARP阻害剤のアジア太平洋市場分析（日本、中国、韓国、インド、東南アジア等）
・乳がんPARP阻害剤の日本市場規模推移
・乳がんPARP阻害剤の中国市場規模推移
・乳がんPARP阻害剤の韓国市場規模推移
・乳がんPARP阻害剤のインド市場規模推移
・乳がんPARP阻害剤の東南アジア市場規模推移
・乳がんPARP阻害剤の南米市場分析（ブラジル、アルゼンチン等）
・乳がんPARP阻害剤の中東・アフリカ市場分析（サウジアラビア、UAE、南アフリカ等）
・乳がんPARP阻害剤の種類別分析/販売量、売上、市場シェア（オラパリブ、タラゾパリブ）
・乳がんPARP阻害剤の用途別分析/市場規模（携帯電話アクセサリー店、3C小売店、個人）
・乳がんPARP阻害剤の市場予測2019年-2024年（地域別予測、種類別予測、用途別予測）
・乳がんPARP阻害剤の販売チャネル・代理店・貿易業者・ディーラー分析

Scope of the Report:
The global PARP Inhibitors for Breast Cancer market is valued at xx million USD in 2018 and is expected to reach xx million USD by the end of 2024, growing at a CAGR of xx% between 2019 and 2024.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of PARP Inhibitors for Breast Cancer.
Europe also play important roles in global market, with market size of xx million USD in 2019 and will be xx million USD in 2024, with a CAGR of xx%.
This report studies the PARP Inhibitors for Breast Cancer market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the PARP Inhibitors for Breast Cancer market by product type and applications/end industries.

Market Segment by Companies, this report covers
AstraZeneca
Everest Pharmaceuticals
Pfizer

Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers
Olaparib
Talazoparib

Market Segment by Applications, can be divided into
Hospital
Clinic
Drug Center
Other

レポート目次

Table of Contents

1 PARP Inhibitors for Breast Cancer Market Overview
1.1 Product Overview and Scope of PARP Inhibitors for Breast Cancer
1.2 Classification of PARP Inhibitors for Breast Cancer by Types
1.2.1 Global PARP Inhibitors for Breast Cancer Revenue Comparison by Types (2019-2024)
1.2.2 Global PARP Inhibitors for Breast Cancer Revenue Market Share by Types in 2018
1.2.3 Olaparib
1.2.4 Talazoparib
1.3 Global PARP Inhibitors for Breast Cancer Market by Application
1.3.1 Global PARP Inhibitors for Breast Cancer Market Size and Market Share Comparison by Applications (2014-2024)
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Drug Center
1.3.5 Other
1.4 Global PARP Inhibitors for Breast Cancer Market by Regions
1.4.1 Global PARP Inhibitors for Breast Cancer Market Size (Million USD) Comparison by Regions (2014-2024)
1.4.1 North America (USA, Canada and Mexico) PARP Inhibitors for Breast Cancer Status and Prospect (2014-2024)
1.4.2 Europe (Germany, France, UK, Russia and Italy) PARP Inhibitors for Breast Cancer Status and Prospect (2014-2024)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) PARP Inhibitors for Breast Cancer Status and Prospect (2014-2024)
1.4.4 South America (Brazil, Argentina, Colombia) PARP Inhibitors for Breast Cancer Status and Prospect (2014-2024)
1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) PARP Inhibitors for Breast Cancer Status and Prospect (2014-2024)
1.5 Global Market Size of PARP Inhibitors for Breast Cancer (2014-2024)
2 Manufacturers Profiles
2.1 AstraZeneca
2.1.1 Business Overview
2.1.2 PARP Inhibitors for Breast Cancer Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 AstraZeneca PARP Inhibitors for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
2.2 Everest Pharmaceuticals
2.2.1 Business Overview
2.2.2 PARP Inhibitors for Breast Cancer Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Everest Pharmaceuticals PARP Inhibitors for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
2.3 Pfizer
2.3.1 Business Overview
2.3.2 PARP Inhibitors for Breast Cancer Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Pfizer PARP Inhibitors for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
3 Global PARP Inhibitors for Breast Cancer Market Competition, by Players
3.1 Global PARP Inhibitors for Breast Cancer Revenue and Share by Players (2014-2019)
3.2 Market Concentration Rate
3.2.1 Top 5 PARP Inhibitors for Breast Cancer Players Market Share
3.2.2 Top 10 PARP Inhibitors for Breast Cancer Players Market Share
3.3 Market Competition Trend
4 Global PARP Inhibitors for Breast Cancer Market Size by Regions
4.1 Global PARP Inhibitors for Breast Cancer Revenue and Market Share by Regions
4.2 North America PARP Inhibitors for Breast Cancer Revenue and Growth Rate (2014-2019)
4.3 Europe PARP Inhibitors for Breast Cancer Revenue and Growth Rate (2014-2019)
4.4 Asia-Pacific PARP Inhibitors for Breast Cancer Revenue and Growth Rate (2014-2019)
4.5 South America PARP Inhibitors for Breast Cancer Revenue and Growth Rate (2014-2019)
4.6 Middle East and Africa PARP Inhibitors for Breast Cancer Revenue and Growth Rate (2014-2019)
5 North America PARP Inhibitors for Breast Cancer Revenue by Countries
5.1 North America PARP Inhibitors for Breast Cancer Revenue by Countries (2014-2019)
5.2 USA PARP Inhibitors for Breast Cancer Revenue and Growth Rate (2014-2019)
5.3 Canada PARP Inhibitors for Breast Cancer Revenue and Growth Rate (2014-2019)
5.4 Mexico PARP Inhibitors for Breast Cancer Revenue and Growth Rate (2014-2019)
6 Europe PARP Inhibitors for Breast Cancer Revenue by Countries
6.1 Europe PARP Inhibitors for Breast Cancer Revenue by Countries (2014-2019)
6.2 Germany PARP Inhibitors for Breast Cancer Revenue and Growth Rate (2014-2019)
6.3 UK PARP Inhibitors for Breast Cancer Revenue and Growth Rate (2014-2019)
6.4 France PARP Inhibitors for Breast Cancer Revenue and Growth Rate (2014-2019)
6.5 Russia PARP Inhibitors for Breast Cancer Revenue and Growth Rate (2014-2019)
6.6 Italy PARP Inhibitors for Breast Cancer Revenue and Growth Rate (2014-2019)
7 Asia-Pacific PARP Inhibitors for Breast Cancer Revenue by Countries
7.1 Asia-Pacific PARP Inhibitors for Breast Cancer Revenue by Countries (2014-2019)
7.2 China PARP Inhibitors for Breast Cancer Revenue and Growth Rate (2014-2019)
7.3 Japan PARP Inhibitors for Breast Cancer Revenue and Growth Rate (2014-2019)
7.4 Korea PARP Inhibitors for Breast Cancer Revenue and Growth Rate (2014-2019)
7.5 India PARP Inhibitors for Breast Cancer Revenue and Growth Rate (2014-2019)
7.6 Southeast Asia PARP Inhibitors for Breast Cancer Revenue and Growth Rate (2014-2019)
8 South America PARP Inhibitors for Breast Cancer Revenue by Countries
8.1 South America PARP Inhibitors for Breast Cancer Revenue by Countries (2014-2019)
8.2 Brazil PARP Inhibitors for Breast Cancer Revenue and Growth Rate (2014-2019)
8.3 Argentina PARP Inhibitors for Breast Cancer Revenue and Growth Rate (2014-2019)
8.4 Colombia PARP Inhibitors for Breast Cancer Revenue and Growth Rate (2014-2019)
9 Middle East and Africa Revenue PARP Inhibitors for Breast Cancer by Countries
9.1 Middle East and Africa PARP Inhibitors for Breast Cancer Revenue by Countries (2014-2019)
9.2 Saudi Arabia PARP Inhibitors for Breast Cancer Revenue and Growth Rate (2014-2019)
9.3 UAE PARP Inhibitors for Breast Cancer Revenue and Growth Rate (2014-2019)
9.4 Egypt PARP Inhibitors for Breast Cancer Revenue and Growth Rate (2014-2019)
9.5 Nigeria PARP Inhibitors for Breast Cancer Revenue and Growth Rate (2014-2019)
9.6 South Africa PARP Inhibitors for Breast Cancer Revenue and Growth Rate (2014-2019)
10 Global PARP Inhibitors for Breast Cancer Market Segment by Type
10.1 Global PARP Inhibitors for Breast Cancer Revenue and Market Share by Type (2014-2019)
10.2 Global PARP Inhibitors for Breast Cancer Market Forecast by Type (2019-2024)
10.3 Olaparib Revenue Growth Rate (2014-2024)
10.4 Talazoparib Revenue Growth Rate (2014-2024)
11 Global PARP Inhibitors for Breast Cancer Market Segment by Application
11.1 Global PARP Inhibitors for Breast Cancer Revenue Market Share by Application (2014-2019)
11.2 PARP Inhibitors for Breast Cancer Market Forecast by Application (2019-2024)
11.3 Hospital Revenue Growth (2014-2019)
11.4 Clinic Revenue Growth (2014-2019)
11.5 Drug Center Revenue Growth (2014-2019)
11.6 Other Revenue Growth (2014-2019)
12 Global PARP Inhibitors for Breast Cancer Market Size Forecast (2019-2024)
12.1 Global PARP Inhibitors for Breast Cancer Market Size Forecast (2019-2024)
12.2 Global PARP Inhibitors for Breast Cancer Market Forecast by Regions (2019-2024)
12.3 North America PARP Inhibitors for Breast Cancer Revenue Market Forecast (2019-2024)
12.4 Europe PARP Inhibitors for Breast Cancer Revenue Market Forecast (2019-2024)
12.5 Asia-Pacific PARP Inhibitors for Breast Cancer Revenue Market Forecast (2019-2024)
12.6 South America PARP Inhibitors for Breast Cancer Revenue Market Forecast (2019-2024)
12.7 Middle East and Africa PARP Inhibitors for Breast Cancer Revenue Market Forecast (2019-2024)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source

List of Tables and Figures

Figure PARP Inhibitors for Breast Cancer Picture
Table Product Specifications of PARP Inhibitors for Breast Cancer
Table Global PARP Inhibitors for Breast Cancer and Revenue (Million USD) Market Split by Product Type
Figure Global PARP Inhibitors for Breast Cancer Revenue Market Share by Types in 2018
Figure Olaparib Picture
Figure Talazoparib Picture
Table Global PARP Inhibitors for Breast Cancer Revenue (Million USD) by Application (2014-2024)
Figure PARP Inhibitors for Breast Cancer Revenue Market Share by Applications in 2018
Figure Hospital Picture
Figure Clinic Picture
Figure Drug Center Picture
Figure Other Picture
Table Global Market PARP Inhibitors for Breast Cancer Revenue (Million USD) Comparison by Regions 2014-2024
Figure North America PARP Inhibitors for Breast Cancer Revenue (Million USD) and Growth Rate (2014-2024)
Figure Europe PARP Inhibitors for Breast Cancer Revenue (Million USD) and Growth Rate (2014-2024)
Figure Asia-Pacific PARP Inhibitors for Breast Cancer Revenue (Million USD) and Growth Rate (2014-2024)
Figure South America PARP Inhibitors for Breast Cancer Revenue (Million USD) and Growth Rate (2014-2024)
Figure Middle East and Africa PARP Inhibitors for Breast Cancer Revenue (Million USD) and Growth Rate (2014-2024)
Figure Global PARP Inhibitors for Breast Cancer Revenue (Million USD) and Growth Rate (2014-2024)
Table AstraZeneca Basic Information, Manufacturing Base and Competitors
Table AstraZeneca PARP Inhibitors for Breast Cancer Type and Applications
Table AstraZeneca PARP Inhibitors for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
Table Everest Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table Everest Pharmaceuticals PARP Inhibitors for Breast Cancer Type and Applications
Table Everest Pharmaceuticals PARP Inhibitors for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
Table Pfizer Basic Information, Manufacturing Base and Competitors
Table Pfizer PARP Inhibitors for Breast Cancer Type and Applications
Table Pfizer PARP Inhibitors for Breast Cancer Revenue, Gross Margin and Market Share (2017-2018)
Table Global PARP Inhibitors for Breast Cancer Revenue (Million USD) by Players (2014-2019)
Table Global PARP Inhibitors for Breast Cancer Revenue Share by Players (2014-2019)
Figure Global PARP Inhibitors for Breast Cancer Revenue Share by Players in 2017
Figure Global PARP Inhibitors for Breast Cancer Revenue Share by Players in 2018
Figure Global Top 5 Players PARP Inhibitors for Breast Cancer Revenue Market Share in 2018
Figure Global Top 10 Players PARP Inhibitors for Breast Cancer Revenue Market Share in 2018
Figure Global PARP Inhibitors for Breast Cancer Revenue (Million USD) and Growth Rate (%) (2014-2019)
Table Global PARP Inhibitors for Breast Cancer Revenue (Million USD) by Regions (2014-2019)
Table Global PARP Inhibitors for Breast Cancer Revenue Market Share by Regions (2014-2019)
Figure Global PARP Inhibitors for Breast Cancer Revenue Market Share by Regions (2014-2019)
Figure Global PARP Inhibitors for Breast Cancer Revenue Market Share by Regions in 2018
Figure North America PARP Inhibitors for Breast Cancer Revenue and Growth Rate (2014-2019)
Figure Europe PARP Inhibitors for Breast Cancer Revenue and Growth Rate (2014-2019)
Figure Asia-Pacific PARP Inhibitors for Breast Cancer Revenue and Growth Rate (2014-2019)
Figure South America PARP Inhibitors for Breast Cancer Revenue and Growth Rate (2014-2019)
Figure Middle East and Africa PARP Inhibitors for Breast Cancer Revenue and Growth Rate (2014-2019)
Table North America PARP Inhibitors for Breast Cancer Revenue by Countries (2014-2019)
Table North America PARP Inhibitors for Breast Cancer Revenue Market Share by Countries (2014-2019)
Figure North America PARP Inhibitors for Breast Cancer Revenue Market Share by Countries (2014-2019)
Figure North America PARP Inhibitors for Breast Cancer Revenue Market Share by Countries in 2018
Figure USA PARP Inhibitors for Breast Cancer Revenue and Growth Rate (2014-2019)
Figure Canada PARP Inhibitors for Breast Cancer Revenue and Growth Rate (2014-2019)
Figure Mexico PARP Inhibitors for Breast Cancer Revenue and Growth Rate (2014-2019)
Table Europe PARP Inhibitors for Breast Cancer Revenue (Million USD) by Countries (2014-2019)
Figure Europe PARP Inhibitors for Breast Cancer Revenue Market Share by Countries (2014-2019)
Figure Europe PARP Inhibitors for Breast Cancer Revenue Market Share by Countries in 2018
Figure Germany PARP Inhibitors for Breast Cancer Revenue and Growth Rate (2014-2019)
Figure UK PARP Inhibitors for Breast Cancer Revenue and Growth Rate (2014-2019)
Figure France PARP Inhibitors for Breast Cancer Revenue and Growth Rate (2014-2019)
Figure Russia PARP Inhibitors for Breast Cancer Revenue and Growth Rate (2014-2019)
Figure Italy PARP Inhibitors for Breast Cancer Revenue and Growth Rate (2014-2019)
Table Asia-Pacific PARP Inhibitors for Breast Cancer Revenue (Million USD) by Countries (2014-2019)
Figure Asia-Pacific PARP Inhibitors for Breast Cancer Revenue Market Share by Countries (2014-2019)
Figure Asia-Pacific PARP Inhibitors for Breast Cancer Revenue Market Share by Countries in 2018
Figure China PARP Inhibitors for Breast Cancer Revenue and Growth Rate (2014-2019)
Figure Japan PARP Inhibitors for Breast Cancer Revenue and Growth Rate (2014-2019)
Figure Korea PARP Inhibitors for Breast Cancer Revenue and Growth Rate (2014-2019)
Figure India PARP Inhibitors for Breast Cancer Revenue and Growth Rate (2014-2019)
Figure Southeast Asia PARP Inhibitors for Breast Cancer Revenue and Growth Rate (2014-2019)
Table South America PARP Inhibitors for Breast Cancer Revenue by Countries (2014-2019)
Table South America PARP Inhibitors for Breast Cancer Revenue Market Share by Countries (2014-2019)
Figure South America PARP Inhibitors for Breast Cancer Revenue Market Share by Countries (2014-2019)
Figure South America PARP Inhibitors for Breast Cancer Revenue Market Share by Countries in 2018
Figure Brazil PARP Inhibitors for Breast Cancer Revenue and Growth Rate (2014-2019)
Figure Argentina PARP Inhibitors for Breast Cancer Revenue and Growth Rate (2014-2019)
Figure Colombia PARP Inhibitors for Breast Cancer Revenue and Growth Rate (2014-2019)
Table Middle East and Africa PARP Inhibitors for Breast Cancer Revenue (Million USD) by Countries (2014-2019)
Table Middle East and Africa PARP Inhibitors for Breast Cancer Revenue Market Share by Countries (2014-2019)
Figure Middle East and Africa PARP Inhibitors for Breast Cancer Revenue Market Share by Countries (2014-2019)
Figure Middle East and Africa PARP Inhibitors for Breast Cancer Revenue Market Share by Countries in 2018
Figure Saudi Arabia PARP Inhibitors for Breast Cancer Revenue and Growth Rate (2014-2019)
Figure UAE PARP Inhibitors for Breast Cancer Revenue and Growth Rate (2014-2019)
Figure Egypt PARP Inhibitors for Breast Cancer Revenue and Growth Rate (2014-2019)
Figure Nigeria PARP Inhibitors for Breast Cancer Revenue and Growth Rate (2014-2019)
Figure South Africa PARP Inhibitors for Breast Cancer Revenue and Growth Rate (2014-2019)
Table Global PARP Inhibitors for Breast Cancer Revenue (Million USD) by Type (2014-2019)
Table Global PARP Inhibitors for Breast Cancer Revenue Share by Type (2014-2019)
Figure Global PARP Inhibitors for Breast Cancer Revenue Share by Type (2014-2019)
Figure Global PARP Inhibitors for Breast Cancer Revenue Share by Type in 2018
Table Global PARP Inhibitors for Breast Cancer Revenue Forecast by Type (2019-2024)
Figure Global PARP Inhibitors for Breast Cancer Market Share Forecast by Type (2019-2024)
Figure Global Olaparib Revenue Growth Rate (2014-2019)
Figure Global Talazoparib Revenue Growth Rate (2014-2019)
Table Global PARP Inhibitors for Breast Cancer Revenue by Application (2014-2019)
Table Global PARP Inhibitors for Breast Cancer Revenue Share by Application (2014-2019)
Figure Global PARP Inhibitors for Breast Cancer Revenue Share by Application (2014-2019)
Figure Global PARP Inhibitors for Breast Cancer Revenue Share by Application in 2018
Table Global PARP Inhibitors for Breast Cancer Revenue Forecast by Application (2019-2024)
Figure Global PARP Inhibitors for Breast Cancer Market Share Forecast by Application (2019-2024)
Figure Global Hospital Revenue Growth Rate (2014-2019)
Figure Global Clinic Revenue Growth Rate (2014-2019)
Figure Global Drug Center Revenue Growth Rate (2014-2019)
Figure Global Other Revenue Growth Rate (2014-2019)
Figure Global PARP Inhibitors for Breast Cancer Revenue (Million USD) and Growth Rate Forecast (2019-2024)
Table Global PARP Inhibitors for Breast Cancer Revenue (Million USD) Forecast by Regions (2019-2024)
Figure Global PARP Inhibitors for Breast Cancer Revenue Market Share Forecast by Regions (2019-2024)
Figure North America PARP Inhibitors for Breast Cancer Revenue Market Forecast (2019-2024)
Figure Europe PARP Inhibitors for Breast Cancer Revenue Market Forecast (2019-2024)
Figure Asia-Pacific PARP Inhibitors for Breast Cancer Revenue Market Forecast (2019-2024)
Figure South America PARP Inhibitors for Breast Cancer Revenue Market Forecast (2019-2024)
Figure Middle East and Africa PARP Inhibitors for Breast Cancer Revenue Market Forecast (2019-2024)

以下、関連資料のご紹介
  • 乳がんCDK4 / 6阻害剤の世界市場予測 2024年：企業別、地域別、種類・用途別（～2024）
    Global CDK4/6 Inhibitors for Breast Cancer Market 2019 by Company, Regions, Type and Application, Forecast to 2024
    B-GIR08C1129 2019年7月 116Pages
    本調査レポートは、乳がんCDK4 / 6阻害剤の世界市場について調べ、まとめました。種類別セグメントは、等、用途別セグメントは、子供、大人等に区分しました。乳がんCDK4 / 6阻害剤の世界市場概観、企業動向、企業別乳がんCDK4 / 6阻害剤シェア、市場規模推移、市場規模予測（2019年-2024...
  • 乳がん用アロマターゼ阻害剤の世界市場予測 2024年：企業別、地域別、種類・用途別（～2024）
    Global Aromatase Inhibitors for Breast Cancer Market 2019 by Company, Regions, Type and Application, Forecast to 2024
    B-GIR08C0374 2019年7月 124Pages
    本調査レポートは、乳がん用アロマターゼ阻害剤の世界市場について調べ、まとめました。種類別セグメントは、等、用途別セグメントは、オートバイ、乗用車、LCV、HCV等に区分しました。乳がん用アロマターゼ阻害剤の世界市場概観、企業動向、企業別乳がん用アロマターゼ阻害剤シェア、市場規模推移、市場規模予測（2...
  • 乳がんPI3K / AKT / mTor経路阻害剤の世界市場予測 2024年：企業別、地域別、種類・用途別（～2024）
    Global PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market 2019 by Company, Regions, Type and Application, Forecast to 2024
    B-GIR08C4432 2019年8月 124Pages
    本調査レポートは、乳がんPI3K / AKT / mTor経路阻害剤の世界市場について調べ、まとめました。種類別セグメントは、テムシロリムス、エベロリムス等、用途別セグメントは、病院、診療所、外来手術センター、診断センター等に区分しました。乳がんPI3K / AKT / mTor経路阻害剤の世界市場...
  • 乳癌用標的薬の世界市場予測 2024年：企業別、地域別、種類・用途別（～2024）
    Global Targeted Drugs for Breast Cancer Market 2019 by Company, Regions, Type and Application, Forecast to 2024
    B-GIR08C5676 2019年7月 135Pages
    本調査レポートは、乳癌用標的薬の世界市場について調べ、まとめました。種類別セグメントは、等、用途別セグメントは、病院、画像診断センター、癌研究所、その他等に区分しました。乳癌用標的薬の世界市場概観、企業動向、企業別乳癌用標的薬シェア、市場規模推移、市場規模予測（2019年-2024年）、主要地域分析...
  • PARP（ポリADPリボースポリメラーゼ）阻害剤の世界市場予測 2019年：メーカー別、地域別、種類・用途別（～2024）
    Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2024
    B-GIR08C4299 2019年8月 122Pages
    本調査レポートは、PARP（ポリADPリボースポリメラーゼ）阻害剤の世界市場について調べ、まとめました。種類別セグメントは、リンパルザ、ゼジュラ、ルブラカ、タルツェナ、その他等、用途別セグメントは、卵巣がん、乳がん、その他等に区分しました。PARP（ポリADPリボースポリメラーゼ）阻害剤の世界市場概...
  • 乳癌用HER-2標的薬の世界市場予測 2024年：企業別、地域別、種類・用途別（～2024）
    Global HER-2 Targeted Drugs for Breast Cancer Market 2019 by Company, Regions, Type and Application, Forecast to 2024
    B-GIR08C2708 2019年8月 115Pages
    本調査レポートは、乳癌用HER-2標的薬の世界市場について調べ、まとめました。種類別セグメントは、トラスツズマブ、ペルツズマブ、ラパチニブ、ネラチニブ、トラスツズマブエムタンシン、ピロチニブ、その他等、用途別セグメントは、病院薬局、小売薬局、オンライン薬局等に区分しました。乳癌用HER-2標的薬の世...
  • 乳癌VEGF標的薬の世界市場予測 2024年：企業別、地域別、種類・用途別（～2024）
    Global VEGF Targeted Drugs for Breast Cancer Market 2019 by Company, Regions, Type and Application, Forecast to 2024
    B-GIR08C6127 2019年8月 119Pages
    本調査レポートは、乳癌VEGF標的薬の世界市場について調べ、まとめました。種類別セグメントは、ベバシズマブ、ソラフェニブ、ラムシルマブ、スニチニブ、アパチニブ等、用途別セグメントは、病院、整形外科クリニック、外来手術センター、診断センター等に区分しました。乳癌VEGF標的薬の世界市場概観、企業動向、...
  • 乳癌用ER標的薬の世界市場予測 2024年：企業別、地域別、種類・用途別（～2024）
    Global ER Targeted Drugs for Breast Cancer Market 2019 by Company, Regions, Type and Application, Forecast to 2024
    B-GIR08C2121 2019年8月 135Pages
    本調査レポートは、乳癌用ER標的薬の世界市場について調べ、まとめました。種類別セグメントは、タモキシフェン、トレミフェン、フルベストラント等、用途別セグメントは、病院、診療所、その他等に区分しました。乳癌用ER標的薬の世界市場概観、企業動向、企業別乳癌用ER標的薬シェア、市場規模推移、市場規模予測（...
  • 乳癌用内分泌療法薬の世界市場予測 2024年：企業別、地域別、種類・用途別（～2024）
    Global Endocrine Therapy Drugs for Breast Cancer Market 2019 by Company, Regions, Type and Application, Forecast to 2024
    B-GIR08C2080 2019年8月 135Pages
    本調査レポートは、乳癌用内分泌療法薬の世界市場について調べ、まとめました。種類別セグメントは、タモキシフェン、アナストロゾール、エキセメスタン、レトロゾール、ゴセレリン、フルベストラント等、用途別セグメントは、工業、農業、航空宇宙、防衛、その他等に区分しました。乳癌用内分泌療法薬の世界市場概観、企業...
  • 世界の転移性乳がんの治療市場：市場規模・現状・予測
    Global Metastatic Breast Cancer Treatment Market Size, Status and Forecast 2019-2025
    QYR9N7553 2019年6月14日 96Pages
    当資料は、転移性乳がんの治療のグローバル市場について調査・分析したレポートで、種類別（化学療法、放射線療法、生物学的標的療法、乳房手術、ホルモン療法）、用途別（病院、診療所、その他）、主要地域別（アメリカ、ヨーロッパ、中国、日本、東南アジア、インド、中南米）の市場規模、市場予測、関連企業情報などが含...